Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (CHOP Therapy) (14 days) for the treatment of non-hodgkin's lymphoma (NHL). The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of Non Hodgkin's Lymphoma (NHL). Rituximab to be included in CD20 positive patients.